- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00875693
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia
This open-label Phase I study is designed to determine the maximum tolerated dose (MTD) for CPX-351 followed by a reduced intensity conditioning regimen and incorporates a dose-escalation schedule that sequentially enrolls 6 dosing cohorts. After the determination of the MTD, the investigator reserves the option to enroll up to 10 additional subjects in an expanded safety cohort(s) at the MTD.
Refractory and relapsed AML patients who meet standard institutional criteria to undergo sequential induction/reduced intensity conditioning allogeneic transplants will be offered a transplant from a related or unrelated donor (full match or 1 antigen mismatch). Cord blood transplants will not be used in this study.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients are included, if they fulfill at least one of the following criteria defining refractory or relapsed AML according to previously established criteria 1-3: (1) Primary induction failure (PIF) after ≥ 2 cycles of chemotherapy. (2) First relapse. (3) Relapse refractory to salvage chemotherapy (4) Second or subsequent relapse.
- Patients with MDS, either refractory anemia with excess blasts (RAEB) I or RAEB II
- Age between 18 and 70 years old.
- Patients must have a Karnofsky Performance Status > 70.
- Each patient must be willing to participate as a research subject and must sign an informed consent form.
- If the patient has a history of a prior malignancy, they must be without any evidence of disease of that prior malignancy for at least 2 years before being eligible for transplant on this protocol. This excludes skin cancers that may have been excised within that 2 year period.
Patients must have adequate physical function measured by:
- Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise.
- Hepatic: < 3x upper limit of normal (ULN) alanine aminotransferase (ALT) and < 1.5 total serum bilirubin, unless liver is involved with the disease or there is congenital benign hyperbilirubinemia.
- Renal: serum creatinine within normal range for age or if serum creatinine is outside the normal range, then creatinine clearance > 60-ml/min.
- Pulmonary: asymptomatic or if symptomatic, diffusing capacity of carbon monoxide (DLCO) > 45% of predicted (corrected for hemoglobin)
Exclusion Criteria:
- Impaired renal function with a measured or calculated creatinine clearance of less than 60 ml/min.
- Impaired hepatic function defined as a bilirubin greater than 1.5 x upper limit of normal or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 x normal.
- Serious active or uncontrolled infection (Infections are controlled when patients are afebrile and hemodynamically stable for 72 hours) or medical condition.
- Women who are pregnant or breast feeding. Women of childbearing age must use adequate contraception and have a negative pregnancy test.
- Impaired pulmonary function with a DLCO less than 45% predicted.
- Impaired cardiac function with an ejection fraction less than 50% of predicted by echocardiogram or multigated acquisition scan (MUGA).
Prior daunorubicin therapy with a cumulative dose of more than 368 mg/m2 or equivalent. The anthracycline agents commonly used in treating myeloid malignancies are doxorubicin, idarubicin and mitoxantron.
For example, a patient who receives 7 + 3 (daunorubicin 180 mg/m2) for induction and MEC regimen (mitoxantrone, etoposide, cytaragine; mitoxantrone 48 mg/m2) for salvage. The cumulative daunorubicin equivalent is 180 + (48x2) = 278 mg/m2.
- Other systemic anticancer therapy or ongoing toxicities from such therapy.
- Patients with a history of and/or current evidence of myocardial impairment (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, congestive heart failure), resulting in heart failure by New York Heart Association Class III or IV staging.
- Patients with Wilson disease or other Copper-related disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A dose of CPX - 351
Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
|
CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
The two drugs are present inside the liposome in a 5:1 molar ratio.
|
Experimental: Arm B dose of CPX-351
Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
|
CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
The two drugs are present inside the liposome in a 5:1 molar ratio.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the toxicity and safety of the regimen
Time Frame: cohort dependent
|
cohort dependent
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0812010140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Thomas Jefferson UniversityAbbVieRecruitingMyelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic SyndromeUnited States
-
Uma BorateRecruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
Clinical Trials on CPX-351
-
French Innovative Leukemia OrganisationAcute Leukemia French Association; French Intergroup of Myeloproliferative...RecruitingAcute Myeloid Leukemia | Myeloproliferative SyndromeFrance
-
Case Comprehensive Cancer CenterActive, not recruitingMyelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myelomonocytic LeukemiaUnited States
-
Jazz PharmaceuticalsIqvia Pty LtdCompleted
-
Groupe Francophone des MyelodysplasiesCompleted
-
Jazz PharmaceuticalsCompletedTherapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
Jazz PharmaceuticalsAdvice Pharma S.r.l.RecruitingAcute Myeloid Leukemia (AML) | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesItaly
-
Yale UniversityWithdrawn
-
Jazz PharmaceuticalsCompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Hematologic MalignancyUnited States, Canada
-
Jazz PharmaceuticalsCompletedAcute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS)United States
-
Jazz PharmaceuticalsApproved for marketingSecondary AMLUnited States